Acusphere, Inc. (ACUS) Stock Price & Analysis
Acusphere, Inc. (ACUS) closed at USD 0 on Thursday, October 22, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0; the Oct 22, 2026 session ranged USD 0–0 on volume of 125 shares. Market capitalization is $3.71M, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, retrieved October 24, 2026 at 00:58 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ACUS.md
Key facts (ACUS)
- Analysts: None.
- Total return with dividends: 1Y +0.0% vs S&P 500 +14.0%; 5Y -90.0% vs S&P 500 +76.9%.
Analysts (ACUS)
Consensus None.
Total return (dividends reinvested) (ACUS)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +0.0% | -90.0% |
| S&P 500 (SPY) | +14.0% | +76.9% |
| Per year | +0.0% | -37.0% |
| Volatility (annualized) | 0.0% | 230.2% |
| Max drawdown | +0.0% (→) | -99.0% (Nov 2021→Nov 2021) |
ACUS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter (ends Jun 2009) | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2009) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 00:58 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 125 shares |
| Market Cap | $3.71M |
| Exchange | PNK |
Technical Analysis (ACUS)
Nexqual's technical model rates ACUS "SELL" based on 0 bullish and 1 bearish signals across 126 daily candles, as of October 24, 2026 at 00:58 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 0) |
Analyst Ratings (ACUS)
Wall Street analysts rate ACUS "None", per Nexqual as of October 24, 2026 at 00:58 UTC.
| Consensus Rating | None |
|---|
Earnings (ACUS)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2008-12-31 | USD -6.7 vs est -3.9 ▼ miss |
| 2008-06-30 | USD -2.5 vs est -2 ▼ miss |
| 2008-03-31 | USD -3 vs est -2.2 ▼ miss |
Source: Nexqual, October 24, 2026 at 00:58 UTC.
Financials & Fundamentals (ACUS)
| Total Revenue | $2.68M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +23.50% |
| Gross Margin | +0.00% |
| Operating Margin | -1034.71% |
| Profit Margin | +0.00% |
| Current Ratio | 1.27 |
| Total Cash | $16.45M |
| Total Debt | $23.25M |
Source: Nexqual, October 24, 2026 at 00:58 UTC.
Financial Health Score (ACUS)
Nexqual rates Acusphere, Inc.'s overall financial health "Mixed" across five dimensions, as of October 24, 2026 at 00:58 UTC.
| Growth | Strong — Revenue +50% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $16M cash vs $23M debt |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Ownership (ACUS)
| Shares Outstanding | 0 |
|---|
Source: Nexqual, October 24, 2026 at 00:58 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUPN | Supernus Pharmaceuticals, Inc. | USD 40.7 | ▼ 3.26% |
| BHC | Bausch Health Companies Inc. | USD 6.44 | ▼ 0.77% |
| HCM | HUTCHMED (China) Limited | USD 14.36 | ▲ 0.56% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.2 | ▼ 4.8% |
| RGC | Regencell Bioscience Holdings L | USD 7.67 | ▼ 21.81% |
| LQDA | Liquidia Corporation | USD 42.65 | ▲ 7.46% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 00:58 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt